Amneal Lines Up Launches As It Builds Out Biosimilars Business
Generics Sales Remain Flat In Q3, But Alymsys Bevacizumab Biosimilar Makes Solid Start
Executive Summary
Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.
You may also be interested in...
Amneal Says Vertical Integration Will Be Key To Compete In Biosimilars
Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.
Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies
As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.
Amneal Reveals Orion As European Partner
Amneal has delivered on promises that it would soon finalize a European partnership by announcing a long-term licensing collaboration with Finnish firm Orion that will also cover Australia and New Zealand.